These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33185630)

  • 1. Pretomanid for the treatment of pulmonary tuberculosis.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2020 Oct; 56(10):655-668. PubMed ID: 33185630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretomanid: First Approval.
    Keam SJ
    Drugs; 2019 Nov; 79(16):1797-1803. PubMed ID: 31583606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
    Stancil SL; Mirzayev F; Abdel-Rahman SM
    Drug Des Devel Ther; 2021; 15():2815-2830. PubMed ID: 34234413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
    Deb U; Biswas S
    Indian J Tuberc; 2021 Apr; 68(2):287-291. PubMed ID: 33845969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
    Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
    Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
    N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
    Aher RB; Sarkar D
    J Biomol Struct Dyn; 2021 Feb; 39(3):889-900. PubMed ID: 31983295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria.
    Zhuang Z; Wan D; Ding J; He S; Zhang Q; Wang X; Yuan Y; Lu Y; Ding CZ; Lynch AS; Upton AM; Cooper CB; Denny WA; Ma Z
    Molecules; 2020 May; 25(10):. PubMed ID: 32456032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
    N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
    Nedelman JR; Salinger DH; Subramoney V; Woolson R; Wade K; Li M; Everitt D; Mendel CM; Spigelman M
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
    Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
    Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Li S-Y; Tyagi S; Soni H; Betoudji F; Converse PJ; Mdluli K; Upton AM; Fotouhi N; Barros-Aguirre D; Ballell L; Jimenez-Navarro E; Nuermberger EL
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0156223. PubMed ID: 38376228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic
    Mota F; Ruiz-Bedoya CA; Tucker EW; Holt DP; De Jesus P; Lodge MA; Erice C; Chen X; Bahr M; Flavahan K; Kim J; Brosnan MK; Ordonez AA; Peloquin CA; Dannals RF; Jain SK
    Nat Commun; 2022 Dec; 13(1):7974. PubMed ID: 36581633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
    Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.